Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study

Amgen reported an update on the Phase 3 DeLLphi-305 trial evaluating IMDELLTRA (tarlatamab-dlle) plus AstraZeneca's Imfinzi (durvalumab) against durvalumab alone as first-line maintenance therapy for patients with extensive-stage disease. The provided article text is truncated before disclosing trial efficacy, safety, or statistical results, limiting assessment of the commercial and investment implications.